EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG …
Jun 6, 2022 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). The ...
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND …
Jul 1, 2024 · FZEC is Eisai’s first antibody drug conjugate (ADC) and that is composed of Eisai’s in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the folate receptor alpha (FRα), and Eisai’s in-house developed anticancer agent eribulin, using an enzymatically cleavable linker.
EISAI AND BRISTOL MYERS SQUIBB ENTER INTO GLOBAL …
TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines ...
Eisai Presents New Findings for Antibody Drug ... - Eisai Newsroom
NUTLEY, N.J., June 5, 2022 /PRNewswire/ -- Eisai announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202).
Eisai inks Bliss ADC deal to challenge AstraZeneca blockbuster
May 8, 2023 · Eisai is joining the HER2 antibody-drug conjugate (ADC) gold rush. After seeing AstraZeneca and Daiichi Sankyo validate the approach, Eisai has struck a $2 billion biobucks deal with Bliss...
Eisai to share oncology pipeline updates at ESMO Congress 2024 | Eisai …
Sep 4, 2024 · In May 2023, Eisai entered into a joint clinical trial collaboration agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, "BlissBio"), for BB-1701, a HER2-targeting antibody drug conjugate (ADC), with option rights for a strategic collaboration.
EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH …
May 8, 2023 · BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2.
Eisai and BMS End ADC Deal, But Eisai Will Continue Development
Jul 3, 2024 · Eisai and Bristol Myers Squibb are ending their $650M collaboration for the co-development and co-commercialization of antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC), due to “ongoing portfolio prioritization efforts within Bristol Myers Squibb (BMS).”
BMS axes Eisai ADC pact 3 years after paying $650M - Fierce …
Jul 1, 2024 · Eisai has regained full rights to the ADC, which is now called farletuzumab ecteribulin (FZEC), and plans to refund “a part of the unused portion of the $200 million” BMS paid to support R&D...
Eisai and Bristol Myers Squibb Enter Into Global Strategic ...
Jun 17, 2021 · Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).